Physician profile
Aleksei V Plotnikov
NPI 1083671036
$14,244.01
in general payments reported to CMS, 2019-2025
67 companies · $1,895 in 2025
The $1,895 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $1,583 · 2021: $1,686 · 2022: $2,241 · 2023: $2,425 · 2024: $2,461 · 2025: $1,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,781.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,623.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,310.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $959.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $715.13 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $711.19 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Daiichi Sankyo INC. | $707.85 | 2019-2024 | Injectafer |
| Amgen INC. | $690.87 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $612.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $563.19 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $555.08 | 2019-2025 | Xifaxan, Trulance |
| Sunovion Pharmaceuticals INC. | $315.08 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $314.26 | 2019-2024 | Xarelto, Spravato |
| Antares Pharma, INC. | $277.40 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Paratek Pharmaceuticals, INC. | $259.73 | 2021-2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $252.61 | 2021-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksei Plotnikov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.